Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|August 15, 2020

Streamlined Two-Step Downstream Process for mAb Purification

Dr. Jukka Kervinen and Bill Evans will discuss a process optimization protocol and a two-step process for the purification of a mAb. Wednesday, Sept. 23, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing until Sept. 23, 2021.

Register free: http://www.biopharminternational.com/bp_w/mAb_purification

Event Overview:

In this webcast discover how standard capillary electrophoresis (CE) methods, including CE– sodium dodecyl sulfate (CE-SDS) methods, are being adapted for the changing targets of the biopharmaceutical industry, as part of the development of new drug modalities such as antibody–drug conjugates, bispecific antibodies and more. The presentation will cover CE basics and show how you can adapt both size-based and charged-based methods to improve resolution and sensitivity needed to detect and profile impurities in various types of protein-based pharmaceuticals.

Key Learning Objectives:

  • Learn how CE-SDS methods are being adapted for new classes of proteins
  • Discover the benefits of laser-induced fluorescence (LIF) detection for the detection of proteins
  • Find out how charge-based separations are being used to analyze the latest biopharmaceutical drugs

Speakers: Bill Evans, Applications Scientist, Process Chromatography, Tosoh Bioscience LLC

Jukka Kervinen, PhD, Scientist, Applications Group Manager, Tosoh Bioscience LLC

Time and Date: Wednesday, Sept. 23, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

On demand available after final airing until Sept. 23, 2021.

Sponsor: Tosoh Bioscience

Register free: http://www.biopharminternational.com/bp_w/mAb_purification


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.